Neogenomics Inc
NASDAQ:NEO

Watchlist Manager
Neogenomics Inc Logo
Neogenomics Inc
NASDAQ:NEO
Watchlist
Price: 17.15 USD 3.75%
Market Cap: 2.2B USD
Have any thoughts about
Neogenomics Inc?
Write Note

Neogenomics Inc
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Neogenomics Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
Neogenomics Inc
NASDAQ:NEO
Other Non-Cash Items
$44.9m
CAGR 3-Years
N/A
CAGR 5-Years
25%
CAGR 10-Years
27%
Thermo Fisher Scientific Inc
NYSE:TMO
Other Non-Cash Items
$700m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Danaher Corp
NYSE:DHR
Other Non-Cash Items
$760m
CAGR 3-Years
23%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Other Non-Cash Items
$19.1m
CAGR 3-Years
4%
CAGR 5-Years
41%
CAGR 10-Years
26%
Agilent Technologies Inc
NYSE:A
Other Non-Cash Items
$186m
CAGR 3-Years
64%
CAGR 5-Years
12%
CAGR 10-Years
1%
IQVIA Holdings Inc
NYSE:IQV
Other Non-Cash Items
$186m
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
N/A
No Stocks Found

Neogenomics Inc
Glance View

Market Cap
2.2B USD
Industry
Life Sciences Tools & Services

NeoGenomics Inc. stands as a formidable player in the field of cancer diagnostics, carving out a niche where precision and innovation meet the urgent needs of patients and healthcare providers. Born out of the vision to advance cancer diagnostics through a blend of clinical testing and state-of-the-art technology, NeoGenomics offers oncologists and pathologists an extensive menu of tests that target genetic markers critical for cancer diagnosis and monitoring. The company operates through a network of high-complexity laboratories in the United States and a growing presence internationally, leveraging its vast technological capabilities to provide services like cytogenetics, molecular testing, and solid tumor testing. This breadth of service allows NeoGenomics to sit squarely at the intersection of patient care and the burgeoning field of personalized medicine. By anchoring its revenue streams primarily in laboratory services, NeoGenomics draws its financial strength from a diverse clientele of community-based healthcare providers, academic institutions, and pharmaceutical companies. The firm capitalizes on the demand for precision diagnostics, as more treatments necessitate an intimate understanding of the tumor’s genetic makeup. This careful calibration between cutting-edge science and clinical practice not only fuels its growth but also positions NeoGenomics as an indispensable partner in the continuum of cancer care. Additionally, its collaborations with pharmaceutical companies open doors to new revenue channels via companion diagnostic development and clinical trial support services, exemplifying an agile approach in the dynamic landscape of oncology.

NEO Intrinsic Value
12.37 USD
Overvaluation 28%
Intrinsic Value
Price

See Also

What is Neogenomics Inc's Other Non-Cash Items?
Other Non-Cash Items
44.9m USD

Based on the financial report for Sep 30, 2024, Neogenomics Inc's Other Non-Cash Items amounts to 44.9m USD.

What is Neogenomics Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
27%

Over the last year, the Other Non-Cash Items growth was 20%.

Back to Top